Durgical
EN
Open the app

Cancer screening in adults by site: what Colombia offers

  • Concept

Only a few cancers have a test that saves lives in healthy people. Knowing which ones, from what age and what a positive leads to is everyday practice.

Updated

See it in 3D: Cervix · Prostate · Sigmoid colon · Stomach

What it is

In Colombia, Resolución 3280 de 2018 (modified by Resolución 276 de 2019) sets screening for four cancers inside the health promotion and maintenance pathway: cervix and colorectum (organised, population screening), breast, and prostate (opportunistic, only after an informed decision). Lung screening with low-dose CT is suggested for heavy smokers by a 2014 MinSalud clinical practice guideline, but it is not a pathway intervention and there is no national programme. Stomach and skin have no population screening: they depend on alarm symptoms, risk groups and the clinical examination. Every positive screen leads to a confirmatory test, never straight to treatment, and people with symptoms or high risk leave the average-risk schedule.

Worked example

  1. Made-up couple at a routine adult visit: Marta, 56, and Jorge, 62, who has smoked a pack a day for 40 years (40 pack-years).
  2. Marta is due an HPV DNA test (negative: next in 5 years), a mammogram every 2 years, a yearly breast exam and a FIT every 2 years.
  3. Jorge is due a FIT every 2 years and is offered PSA with a rectal exam after a talk on benefits and harms; first of all he is helped to stop smoking.
  4. His smoking (40 pack-years, age 62) fits the 2014 guideline's low-dose CT criteria, but it is not a pathway benefit, so it is discussed, not ordered by default.
  5. The PSA talk in numbers (USPSTF 2018, men 55–69, per 1,000 screened over about 13 years): about 1.3 prostate cancer deaths and 3 metastatic cases avoided.
  6. The other side: about 240 have a positive PSA, 220 a biopsy, 100 a diagnosis (20–50% of them overdiagnosed); about 50 sexual dysfunction, 15 incontinence.
  7. Reading: about 1 death avoided against dozens of men harmed per 1,000 is a choice of values, which is why the resolution asks for an informed decision.
  8. Marta's FIT comes back positive: not a cancer diagnosis but a priority colonoscopy, where an adenoma found can be removed and the cancer prevented.

Average-risk adult screening by site in Colombia (Res. 3280 de 2018 unless stated)

SiteWhoTest and intervalA positive leads toStatus in Colombia
CervixWomen 25–29 (cytology) and 30–65 (HPV DNA)Cytology every 3 years after a negative; HPV DNA every 5 years; 30–50 in dispersed areas: visual inspection with acetic acid and LugolHPV positive: triage cytology from the same visit, then colposcopy and biopsy; visual inspection positive: treatment in the same visitOrganised, mandatory
BreastWomen from 40 (exam) and 50–69 (mammogram)Clinical breast exam at least yearly; two-view mammogram every 2 yearsBI-RADS 0: more imaging; 3: follow-up on the breast cancer route; 4–5: active recall and biopsyOrganised
ColorectumMen and women 50–75 at average riskFIT (one sample) every 2 years, or colonoscopy every 10 years where availableActive recall and colonoscopy with biopsy, with priorityOrganised, population
ProstateMen 50–75; from 40 with family history, risk factors or findings: risk assessmentPSA plus digital rectal exam, at intervals of no less than 5 yearsRaised PSA with normal exam: repeat within 6 months, urology if still raised; abnormal exam: urology within 4 weeksOpportunistic, informed shared decision
Lung55–74, at least 30 pack-years, smoking now or quit under 15 years agoLow-dose CT yearly; stop after 3 consecutive negativesNodule work-up by a multidisciplinary teamMinSalud guideline 2014 (weak suggestion); not in Res. 3280
StomachNo average-risk screeningNone; prompt endoscopy for alarm symptoms (weight loss, dysphagia, bleeding, anaemia)BiopsyNo population programme
SkinNo population screeningSkin inspected at the routine adult assessment (sun damage, actinic keratoses)Biopsy of a suspicious lesionNo separate programme

Markers

  • HPV DNA test
  • Mammography
  • FIT
  • PSA
  • Low-dose CT

In practice

  • Symptoms are not screening: a woman with a breast lump or a man with rectal bleeding gets a diagnostic work-up at any age, outside the schedule.
  • Higher risk leaves the average schedule: family history, hereditary syndromes, inflammatory bowel disease or previous polyps go to the cancer risk pathway, with earlier and more frequent tests.
  • Screening also stops: cervix at 65 if HPV tests in the past 5 years were negative; mammography at 69; colorectal and prostate at 75.
  • Gastric cancer is a leading cause of cancer death in parts of Colombia, such as the Andean south, yet healthy adults are not screened by endoscopy: alarm symptoms lead to prompt endoscopy.
  • In smokers, stopping smoking does more than any scan, and a negative low-dose CT is not permission to keep smoking.

Common pitfalls

  • Screening a person who has symptoms instead of investigating them.
  • Ordering the test and never acting on the result: Res. 3280 requires active recall of everyone with a positive.
  • Using tumour markers such as CEA or CA-125 as screening tests: they have no screening role in average-risk adults.
  • Testing for HPV before 30: infections are common and clear on their own at that age, so positives mostly mean transient infection.

Common traps

  • PSA screening is a routine test like a mammogram: Res. 3280 makes it opportunistic and conditional on an informed, shared decision, because its benefit is small and overdiagnosis is common
  • A positive FIT or HPV test means cancer: it is a reason for the confirmatory step (colonoscopy, or triage cytology and colposcopy), and most positives are not cancer
  • Colombia screens heavy smokers with low-dose CT through the RIAS: the 2014 MinSalud guideline suggests offering it, but it is not a pathway intervention and there is no national programme
  • Because gastric cancer is common in Colombia, healthy adults get screening endoscopies: there is no population programme, and endoscopy is for alarm symptoms or defined risk
  • Every screening test prevents cancer: only screens that remove precursors (cervix, colorectum) lower incidence; the others find cancer earlier and lower only mortality

Test yourself

Think of the answer, then tap the question to see it.

Why can cervical and colorectal screening lower the number of new cancers, while mammography cannot?

They find precursors (high-grade cervical lesions, adenomas) that are removed before they become cancer; mammography finds cancers that already exist, so it can only lower mortality.

A 58-year-old man asks for a PSA test. What does Res. 3280 require before it is ordered?

An explanation of its potential benefits and harms and an agreed, informed decision; then PSA with a digital rectal exam, at intervals of no less than 5 years.

A 52-year-old woman's FIT is positive. What happens next?

She is actively contacted and given a priority colonoscopy (with biopsy if needed); the FIT only flags higher probability, it does not diagnose cancer.

A 63-year-old who smoked 35 pack-years and quit 5 years ago asks about lung screening. What is the Colombian position?

The 2014 MinSalud guideline suggests (weak recommendation) offering yearly low-dose CT to people like him after explaining benefits and risks, but it is not a Res. 3280 pathway intervention and there is no national programme.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of epidemiology

Educational content on epidemiological and statistical methods; the examples use made-up numbers to teach the calculation. Not a clinical or legal guide: current Colombian rules are in the official sources.

Sources: Resolución 3280 de 2018: lineamientos técnicos y operativos de la Ruta de Promoción y Mantenimiento de la Salud (compiled text with the changes of Resolución 276 de 2019) (Ministerio de Salud y Protección Social de Colombia (compiled text, JEP normograma), 2018); Guía de práctica clínica para la detección temprana, diagnóstico, estadificación y tratamiento del cáncer de pulmón. Guía para profesionales de la salud (GPC 2014-36) (Ministerio de Salud y Protección Social – Colciencias, 2014); Prostate Cancer: Screening. Final Recommendation Statement (U.S. Preventive Services Task Force, 2018); Incidence and mortality by cancer in the Pasto municipality, Colombia. 2013-2017 (Colombia Médica, 2022).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.